Redeye briefly comments on Navigo announcing several leadership changes.
Redeye initiates coverage of Nekkar, an industrial technology group offering ocean-based technologie...
Redeye comments on the continued expansion into California with a new collaboration with United Heal...
Redeye comments on the published interim data from the MASCC/AFSOS/ISOO 2004 annual meeting in Lille...
The Danish Systemic Risk Council recommends that the Faroe systemic risk buffer is hiked to 3% (curr...
22% sales growth (ABGSCe +24%), losses to gradually improve EBIT ests roughly unchanged, 5-8% margin...
Redeye comments on Medivir’s update from ESMO GI, showing improvements in fostrox’ TTP.
Redeye provides a brief comment on the selection of a new drug candidate.
ODI Pharma announced on June 25th that the company has completed a first delivery of products to the...
PMDS has revised the 2026 sales target, which is 160% higher at SEK 260m (SEK 100m) in terms of recu...
Redeye initiates coverage of CTEK, a market leader within premium low-voltage chargers that is lever...
Investors House announced today that it has divested its 1/3 stake in Jyväskylän Kukkulan Kehitys Oy...
We forecast 21% y-o-y ARR growth and 15% adj. EBITDA margin.
Q2e: 6% organic sales growth y-o-y, 9% adj. EBITA margin Expect a softer Q2, partly on further marke...
Redeye leaves a comment following today’s announcement of the outcome of Alzinova’s recent rights is...
Summarising an eventful H1'24 Many players in the Parkinson's therapy game.
We make minor changes to adjusted EBITA for 2024E-26E ahead of Q2.
Redeye provides a comment on the outcome in Respiratorius’ rights issue, announced earlier this afte...
Redeye comments on Truecaller ahead of its Q2 results, which are due on 19 July.
The European Medicines Agency (EMA) has approved Cereno Scientific’s Clinical Trial Application (CTA...
